Basic information
- Standard SMILES
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C- InChIKey
LEBVLXFERQHONN-UHFFFAOYSA-N- Molecular formula
- C18H28N2O
- Average molar mass
- 288.4 g/mol
- Monoisotopic mass
- 288.22016352
Overview
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is a piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. It is a piperidinecarboxamide, a tertiary amino compound and an aromatic amide. It is a conjugate base of a 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium.
Names & identifiers
- Preferred name
- Bupivacaine (USAN:INN:BAN)
- IUPAC
- 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
- English name
- Bupivacaine
- Molecular formula
- C18H28N2O
- Molecular weight
- 288.43
Names & synonyms
Show more names
Database identifiers
- CAS
2180-92-9、38396-39-3- PubChem CID
- 2474
- DTXSID
DTXSID2022703- ChEBI
CHEBI:77431- UNII
- Y8335394RO
- Nikkaji
- J7.351B
Properties
Computed structural properties
- XLogP
- 3.4
- Topological polar surface area
- 32.3 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 2
- Rotatable bonds
- 5
- Heavy atoms
- 21
- Formal charge
- 0
- Complexity
- 321
Experimental & physicochemical properties
Collision Cross Section
173.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
180.07 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Physicochemical properties
- Melting point
- 107.5 · 107.5-108°
- Boiling point
- 430.65 °C · 430.65°C (rough estimate)
- Density
- 1.0238 · 1.0238 (rough estimate)
- refractive index
- 1.57 · 1.5700 (estimate)
- pka
- 8.09 · 8.09; also reported as 8.17(at 25℃)
- Water Solubility
- 101.5 mg/L · 101.5mg/L(25 ºC)
- InChI
- InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
- InChIKey
- LEBVLXFERQHONN-UHFFFAOYSA-N
- SMILES
- C1(CCCCN1CCCC)C(=O)NC1C(C)=CC=CC=1C
- CAS DataBase Reference
- 2180 · 2180-92-9(CAS DataBase Reference)
- EWG's Food Scores
- 1 · 1
- NCI Dictionary of Cancer Terms
- Marcaine
- FDA UNII
- 8335394 RO · Y8335394RO
- NCI Drug Dictionary
- Marcaine
- ATC code
- 1 BB01,N01BB51 · N01BB01,N01BB51
- NIST Chemistry Reference
- 2 · 2-Piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-(2180-92-9)
- EPA Substance Registry System
- 2 · 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- (2180-92-9)
- Symbol(GHS)
- 7 · GHS07,GHS05,GHS06
- Signal word
- Danger
- Hazard statements
- 315 · H315-H310-H318-H330-H300
- Precautionary statements
- 262 · P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P280-P305+P351+P338-P310-P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501
- Hazard Codes
- T+
- Risk Statements
- 26 · 26/27/28-38-41
- Safety Statements
- 22 · 22-26-36/37/39-45
- RIDADR
- 2811 · 2811
Safety & regulation
Safety data
- ridadr
- 2811
- risk_code
- 26/27/28-38-41
- Signal word
- Danger
- Symbol(GHS)
- GHS07,GHS05,GHS06
- hazard_code
- T+
- safety_code
- 22-26-36/37/39-45
- Hazard statements
- H315-H310-H318-H330-H300
- Precautionary statements
- P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P280-P305+P351+P338-P310-P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501
Chemistry & industry
Pharmacology
Uses & manufacturing
Applications
UsesAnesthetic (local).
UsesLike lidocaine and mepivacaine, bupivacaine is used in infiltration, spinal, and epidural anesthesia in blocking nerve transmission. Its most distinctive property is its long-lasting action. It is used for surgical intervention in urology and in lower thoracic surgery from 3 to 5 h in length, and in abdominal surgery lasting from 45 to 60 min. It is used to block the trifacial nerve, the sacral and brachial plexuses, in resetting dislocations, in epidural anesthesia, and during Cesarian sections.
General DescriptionBupivacaine was synthesized simultaneously with mepivacainein 1957 but was at first overlooked because of the increasedtoxicity compared with mepivacaine. When themethyl on the cyclic amine of mepivacaine is exchanged fora butyl group the lipophilicity, potency and the duration ofaction all increase. Literature reports of cardiovascular toxicity,including severe hypotension and bradycardia, areabundant in the literature.91 Bupivacaine is highly bound toplasma proteins (95%), and thus the free concentration mayremain low until all of the protein binding sites are occupied.After that point, the plasma levels of bupivacaine rise rapidlyand patients may progress to overt cardiac toxicity withoutever showing signs of CNS toxicity. The cardiotoxicity ofbupivacaine is a result of its affinity to cardiac tissues and itsability to depress electrical conduction and predispose theheart to reentry types of arrhythmias. The cardiotoxicity ofbupivacaine was found to be significantly more prominentwith the “R” isomer, or the racemic mixture, thus the “S”stereoisomer is now on the market as levobupivacaine.
Upstream & downstream products
Upstream raw materials
Suppliers50 total
Additional notes
DefinitionChEBI: 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is a piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. It is a piperidinecarboxamide, an aromatic amide and a tertiary amino compound. It is a conjugate base of a 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium.
Related reactions
Linked notes
Loading…